Jounce Therapeutics, Inc.
Records under this name other than the patents Jounce Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 7 of 7 · Back to Jounce Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,692,038 | Antibodies That Bind Chemokine (C-C Motif) Receptor 8 (CCR8) Formerly held In force · High confidence | In force | High confidence | |
| US 12,297,282 | Nucleic Acids Encoding, and Methods of Producing, Antibodies That Bind Human Chemokine (C-C Motif) Receptor 8 (CCR8) Formerly held In force · High confidence | In force | High confidence | |
| US 10,023,635 | Antibodies to Icos Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 11,384,147 | Anti-PD-1 Antibodies and Uses Thereof Lapsed on the fee record Ended Jul 12, 2026 · High confidence | Lapsed on the fee record | Ended Jul 12, 2026 | High confidence |
| US 11,359,019 | Antibodies to LILRB2 Lapsed on the fee record Ended Jun 14, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2026 | USPTO record |
| US 11,292,840 | Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist Lapsed on the fee record Ended Apr 5, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 5, 2026 | USPTO record |
| US 10,968,277 | Gene signatures for determining ICOS expression Lapsed on the fee record Ended Apr 6, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 6, 2025 | USPTO record |